The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
Antibody therapeutics: isotype and glycoform selection
Abstract
Recombinant monoclonal antibody (rMAb) therapy may be instituted to achieve one of two broad outcomes: i) killing of cells or organisms (e.g., cancer cells, bacteria); and ii) neutralisation of soluble molecules (e.g., cytokines in chronic disease or toxins in infection). The choice of rMAb isotype is a critical decision in the development of a therapeutic antibody as it will determine the biological activities triggered in vivo. It is not possible, however, to accurately predict the in vivo activity because multiple parameters impact on the functional outcome, for example, IgG subclass, IgG-Fc glycoform, epitope density, cellular Fc receptors polymorphisms and so on. The present understanding of the molecular interactions between IgG-Fc and effector ligands in vitro has allowed the generation of new antibody structures with altered/improved effector function profiles that may prove optimal for given disease indications. Thus, when maximal antibody-dependent cell-mediated cytotoxicity activity is indicated a non-fucosylated IgG1 format may be optimal; when minimal activity is indicated an aglycosylated IgG2 may be the form of choice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835
Ravetch, J. V., & Bolland, S. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.275 · Cited by 1,657
Deisenhofer, J. (1981) · PubMed · Cited by 1,422
Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210665200 · Cited by 1,413 · cited 1×
“These activities are critically dependent on IgG-Fc N-linked glycosylation and, in part, on individual antibody glycoforms [3,13-20] .”
BackgroundDeisenhofer, J. (1981) · Biochemistry · doi:10.1021/bi00512a001 · Cited by 1,333
Shields, R. L., Namenuk, A. K., Hong, K., Meng, Y. G., Rae, J., Briggs, J., Xie, D., Lai, J., Stadlen, A., Li, B., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009483200 · Cited by 1,161
Potent antibody therapeutics by design
Carter, P. J. (2006) · Nature Reviews Immunology · doi:10.1038/nri1837 · Cited by 1,099
Fcγ Receptors: Old Friends and New Family Members
Nimmerjahn, F., & Ravetch, J. V. (2006) · Immunity · doi:10.1016/j.immuni.2005.11.010 · Cited by 1,072
Engineered antibody Fc variants with enhanced effector function
Lazar, G. A., Dang, W., Karki, S., Vafa, O., Peng, J. S., Hyun, L., Chan, C., Chung, H. S., Eivazi, A., Yoder, S. C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508123103 · Cited by 803
Koene, H. R., Kleijer, M., Algra, J., Roos, D., E.G.Kr. von dem Borne, A., & de Haas, M. (1997) · Blood · doi:10.1182/blood.v90.3.1109 · Cited by 794
Umaña, P., Jean–Mairet, J., Moudry, R., Amstutz, H., & Bailey, J. E. (1999) · Nature Biotechnology · doi:10.1038/6179 · Cited by 764
Monoclonal antibody successes in the clinic
Reichert, J. M., Rosensweig, C. J., Faden, L. B., & Dewitz, M. C. (2005) · Nature Biotechnology · doi:10.1038/nbt0905-1073 · Cited by 733
The 3.2-Å crystal structure of the human IgG1 Fc fragment–FcγRIII complex
Sondermann, P., Huber, R., Oosthuizen, V., & Jacob, U. (2000) · Nature · doi:10.1038/35018508 · Cited by 719
Krapp, S., Mimura, Y., Jefferis, R., Huber, R., & Sondermann, P. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)01250-0 · Cited by 674
Self-citationTeeling, J. L. (2004) · Blood · doi:10.1182/blood-2004-01-0039 · Cited by 630
The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20
Teeling, J. L., Mackus, W. J. M., Wiegman, L. J. J. M., van den Brakel, J. H. N., Beers, S. A., French, R. R., van Meerten, T., Ebeling, S., Vink, T., Slootstra, J. W., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.1.362 · Cited by 609
Brüggemann, M., Williams, G. T., Bindon, C. I., Clark, M. R., Walker, M. R., Jefferis, R., Waldmann, H., & Neuberger, M. S. (1987) · The Journal of experimental medicine · doi:10.1084/jem.166.5.1351 · Cited by 607
Self-citationYamane‐Ohnuki, N., Kinoshita, S., Inoue‐Urakubo, M., Kusunoki, M., Iida, S., Nakano, R., Wakitani, M., Niwa, R., Sakurada, M., Uchida, K., et al. (2004) · Biotechnology and Bioengineering · doi:10.1002/bit.20151 · Cited by 572
Glycosylation of Recombinant Antibody Therapeutics
Jefferis, R. (2008) · Biotechnology Progress · doi:10.1021/bp040016j · Cited by 526
Self-citationHumanization of yeast to produce complex terminally sialylated glycoproteins
Hamilton, S. R., Davidson, R. C., Sethuraman, N., Nett, J. H., Jiang, Y., Rios, S., Bobrowicz, P., Stadheim, T. A., Li, H., Choi, B.-K., et al. (2006) · Science · doi:10.1126/science.1130256 · Cited by 511
Glycoengineering: The effect of glycosylation on the properties of therapeutic proteins
Sinclair, A. M., & Elliott, S. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20319 · Cited by 461
Aalberse, R. C., & Schuurman, J. (2002) · Immunology · doi:10.1046/j.0019-2805.2001.01341.x · Cited by 449
Anolik, J. H., Campbell, D., Felgar, R. E., Young, F., Sanz, I., Rosenblatt, J., & Looney, R. J. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10764 · Cited by 429
Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor
Cox, K. M., Sterling, J. D., Regan, J. T., Gasdaska, J. R., Frantz, K. K., Peele, C. G., Black, A., Passmore, D., Moldovan-Loomis, C., Srinivasan, M., et al. (2006) · Nature Biotechnology · doi:10.1038/nbt1260 · Cited by 421
Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels
Vaccaro, C., Zhou, J., Ober, R. J., & Ward, E. S. (2005) · Nature Biotechnology · doi:10.1038/nbt1143 · Cited by 407
Crystal Structure at 2.8 Å of an FcRn/Heterodimeric Fc Complex
Martin, W. L., West, A. P., Gan, L., & Bjorkman, P. J. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00230-1 · Cited by 391
Human antibody–Fc receptor interactions illuminated by crystal structures
Woof, J. M., & Burton, D. R. (2004) · Nature Reviews Immunology · doi:10.1038/nri1266 · Cited by 387
The Biology of CD20 and Its Potential as a Target for mAb Therapy
Cragg, M. S., Walshe, C. A., Ivanov, A. O., & Glennie, M. J. (2004) · Current Directions in Autoimmunity · doi:10.1159/000082102 · Cited by 364
The Structure of a Human Type III Fcγ Receptor in Complex with Fc
Radaev, S., Motyka, S., Fridman, W.-H., Sautes-Fridman, C., & Sun, P. D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100350200 · Cited by 354
Parren, P. W., Warmerdam, P. A., Boeije, L. C., Arts, J., Westerdaal, N. A., Vlug, A., Capel, P. J., Aarden, L. A., & van de Winkel, J. G. (1992) · Journal of Clinical Investigation · doi:10.1172/jci116022 · Cited by 346
Davies, J., Jiang, L., Pan, L., LaBarre, M. J., Anderson, D., & Reff, M. (2001) · Biotechnology and Bioengineering · doi:10.1002/bit.1119 · Cited by 327
Strasser, R., Altmann, F., Mach, L., Glössl, J., & Steinkellner, H. (2004) · FEBS Letters · doi:10.1016/s0014-5793(04)00150-4 · Cited by 321
Ferrara, C., Brünker, P., Suter, T., Moser, S., Püntener, U., & Umaña, P. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.20777 · Cited by 305
FcγR polymorphisms: Implications for function, disease susceptibility and immunotherapy
Van Sorge, N. M., Van Der Pol, W., & Van De Winkel, J. G. J. (2003) · Tissue Antigens · doi:10.1034/j.1399-0039.2003.00037.x · Cited by 294
Qian, J., Liu, T., Yang, L., Daus, A., Crowley, R., & Zhou, Q. (2007) · Analytical Biochemistry · doi:10.1016/j.ab.2007.01.023 · Cited by 291
An Engineered Human IgG1 Antibody with Longer Serum Half-Life
Hinton, P. R., Xiong, J. M., Johlfs, M. G., Tang, M. T., Keller, S., & Tsurushita, N. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.1.346 · Cited by 282
Niwa, R., Natsume, A., Uehara, A., Wakitani, M., Iida, S., Uchida, K., Satoh, M., & Shitara, K. (2005) · Journal of Immunological Methods · doi:10.1016/j.jim.2005.08.009 · Cited by 244
Role of Oligosaccharide Residues of IgG1-Fc in FcγRIIb Binding
Mimura, Y., Sondermann, P., Ghirlando, R., Lund, J., Young, S. P., Goodall, M., & Jefferis, R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m107478200 · Cited by 236 · cited 2×
“Thus, effector mechanisms mediated through Fc γ RI, Fc γ RII, Fc γ RIII and C1q are severely compromised or ablated for aglycosylated or deglycosylated forms of IgG [13,19,20] .”
BackgroundSelf-citationLouis, E., El Ghoul, Z., Vermeire, S., Dall'Ozzo, S., Rutgeerts, P., Paintaud, G., Belaiche, J., De Vos, M., Van Gossum, A., Colombel, J. ‐., et al. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.01871.x · Cited by 224
Targeted knockouts of Physcomitrella lacking plant‐specific immunogenic N‐glycans
Koprivova, A., Stemmer, C., Altmann, F., Hoffmann, A., Kopriva, S., Gorr, G., Reski, R., & Decker, E. L. (2004) · Plant Biotechnology Journal · doi:10.1111/j.1467-7652.2004.00100.x · Cited by 219
Lund, J., Takahashi, N., Pound, J. D., Goodall, M., & Jefferis, R. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.11.4963 · Cited by 216
Self-citationIida, S., Misaka, H., Inoue, M., Shibata, M., Nakano, R., Yamane-Ohnuki, N., Wakitani, M., Yano, K., Shitara, K., & Satoh, M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2619 · Cited by 206
Preparative expression of secreted proteins in bacteria: status report and future prospects
Georgiou, G., & Segatori, L. (2005) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2005.07.008 · Cited by 206
VALIM, Y. M. L., & LACHMANN, P. J. (2008) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.1991.tb08115.x · Cited by 204
Wacker, M., Feldman, M. F., Callewaert, N., Kowarik, M., Clarke, B. R., Pohl, N. L., Hernandez, M., Vines, E. D., Valvano, M. A., Whitfield, C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509207103 · Cited by 194
M. Cardarelli, M. Q. (2002) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-001-0247-1 · Cited by 189
Biopharmaceutical production in plants: problems, solutions and opportunities
Gomord, V., Chamberlain, P., Jefferis, R., & Faye, L. (2005) · Trends in Biotechnology · doi:10.1016/j.tibtech.2005.09.003 · Cited by 186
Self-citationHolland, M., Yagi, H., Takahashi, N., Kato, K., Savage, C. O. S., Goodall, D. M., & Jefferis, R. (2006) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2005.11.021 · Cited by 184
Self-citationLifely, M. R., Hale, C., Boyce, S., Keen, M. J., & Phillips, J. (1995) · Glycobiology · doi:10.1093/glycob/5.8.813 · Cited by 178
Michaelsen, T. E., Garred, P., & Aase, A. (1991) · European Journal of Immunology · doi:10.1002/eji.1830210103 · Cited by 176
Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies
Satoh, M., Iida, S., & Shitara, K. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.11.1161 · Cited by 175
Production technologies for monoclonal antibodies and their fragments
Andersen, D. C., & Reilly, D. E. (2004) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2004.08.002 · Cited by 162
Verı́, M.-C., Gorlatov, S. N., Li, H., Burke, S., Johnson, S., Stavenhagen, J. B., Stein, K. E., Bonvini, E., & Koenig, S. (2007) · Immunology · doi:10.1111/j.1365-2567.2007.02588.x · Cited by 158
Renaissance of cancer therapeutic antibodies
Glennie, M. J., & van de Winkel, J. G. J. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02714-4 · Cited by 155
Impact of variable domain glycosylation on antibody clearance: An LC/MS characterization
Huang, L., Biolsi, S., Bales, K. R., & Kuchibhotla, U. (2005) · Analytical Biochemistry · doi:10.1016/j.ab.2005.11.012 · Cited by 144
Modulation of the Effector Functions of a Human IgG1 through Engineering of Its Hinge Region
Dall’Acqua, W. F., Cook, K. E., Damschroder, M. M., Woods, R. M., & Wu, H. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.2.1129 · Cited by 138
Jones, A. J. S., Papac, D. I., Chin, E. H., Keck, R. G., Baughman, S. A., Lin, Y. S., Kneer, J., & Battersby, J. E. (2007) · Glycobiology · doi:10.1093/glycob/cwm017 · Cited by 137
YOUINGS, A., Chang, S.-C., Dwek, R. A., & Scragg, I. G. (1996) · Biochemical Journal · doi:10.1042/bj3140621 · Cited by 136
The structural requirements for complement activation by IgG: does it hinge on the hinge?
Brekke, O. H., Michaelsen, T. E., & Sandlie, I. (1995) · Immunology Today · doi:10.1016/0167-5699(95)80094-8 · Cited by 135
Preithner, S., Elm, S., Lippold, S., Locher, M., Wolf, A., da Silva, A. J., Baeuerle, P. A., & Prang, N. S. (2005) · Molecular Immunology · doi:10.1016/j.molimm.2005.07.010 · Cited by 131
Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis
Wong, J. B., Singh, G., & Kavanaugh, A. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01243-3 · Cited by 129
Mirick, G. R., Bradt, B. M., DeNardo, S. J., & DeNardo, G. L. (2004) · PubMed · Cited by 124
Suzuki, E., Niwa, R., Saji, S., Muta, M., Hirose, M., Iida, S., Shiotsu, Y., Satoh, M., Shitara, K., Kondo, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1335 · Cited by 124
Molecular basis of IgG subclass deficiency
Pan‐Hammarström, Q., & Hammarström, L. L. G. (2000) · Immunological Reviews · doi:10.1034/j.1600-065x.2000.17815.x · Cited by 123
Garred, P., Michaelsen, T. E., & Aase, A. (1989) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.1989.tb01225.x · Cited by 112
HOLLAND, M., Hewins, P., Goodall, M. D., Adu, D., Jefferis, R., & Savage, C. O. S. (2004) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2004.02566.x · Cited by 97
Self-citationMarcus, R. E., & Hagenbeek, A. (2006) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2006.00789.x · Cited by 91
Baker, M. (2005) · Nature Biotechnology · doi:10.1038/nbt0905-1065 · Cited by 90
Miescher, S., Spycher, M. O., Amstutz, H., et al. (2004) · Blood · doi:10.1182/blood-2003-11-3929 · Cited by 90
Pulmonary administration of therapeutic proteins using an immunoglobulin transport pathway
Bitonti, A. J., & Dumont, J. A. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.07.015 · Cited by 89
Interactions of Immunoglobulins Outside the Antigen-Combining Site
Nezlin, R. S., & Ghetie, V. F. (2004) · Advances in immunology · doi:10.1016/s0065-2776(04)82004-2 · Cited by 85
Lin, T. S., Flinn, I. W., Modali, R., Lehman, T. A., Webb, J. L., Waymer, S., Moran, M. E., Lucas, M. S., Farag, S. S., & Byrd, J. C. (2004) · Blood · doi:10.1182/blood-2004-02-0651 · Cited by 82
Saltz, L. B., Easley, C., & Kirkpatrick, P. N. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2204 · Cited by 78
Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells
Cole, M. S., Anasetti, C., & Tso, J. Y. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.7.3613 · Cited by 73
Klitgaard, J. L., Coljee, V. W., Andersen, P. S., Rasmussen, L. K., Nielsen, L. S., Haurum, J., & Bregenholt, S. (2006) · Journal of Immunology · doi:10.4049/jimmunol.177.6.3782 · Cited by 71
Rodrı́guez, M. E., van der Pol, W. L., Sanders, E. A. M., & van de Winkel, J. G. J. (1999) · The Journal of Infectious Diseases · doi:10.1086/314603 · Cited by 71
Nechansky, A., Schuster, M., Jost, W. H., Siegl, P., Wiederkum, S., Gorr, G., & Kircheis, R. (2006) · Molecular Immunology · doi:10.1016/j.molimm.2006.08.013 · Cited by 70
Voice, J. K., & Lachmann, P. J. (1997) · European Journal of Immunology · doi:10.1002/eji.1830271008 · Cited by 55
Anderson, C. L. (1989) · Clinical Immunology and Immunopathology · doi:10.1016/0090-1229(89)90071-8 · Cited by 53
Natalizumab and the role of α4-integrin antagonism in the treatment of multiple sclerosis
O'Connor, P. W. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.1.123 · Cited by 53
Alete, D. E., Racher, A. J., Birch, J. R., Stansfield, S. H., James, D. C., & Smales, C. M. (2005) · PROTEOMICS · doi:10.1002/pmic.200500019 · Cited by 51
Michaelsen, T. E., Brekke, O. H., Aase, A., Sandin, R., Bremnes, B., & Sandlie, I. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.20.9243 · Cited by 35
Smalling, R., Foote, M., Molineux, G., Swanson, S. J., & Elliott, S. (2004) · Biotechnology annual review · doi:10.1016/s1387-2656(04)10008-2 · Cited by 33
Plant Proteomics and Glycosylation
Fitchette, A., Dinh, O. T., Faye, L. J.-Y., & Bardor, M. (2006) · Humana Press eBooks · doi:10.1385/1-59745-227-0:317 · Cited by 29
Helguera, G. F., Rodríguez, J. A., & Penichet, M. L. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0488 · Cited by 29
Effect of Gm allotypes on lgG2 antibody responses and lgG2 concentrations in children and adults
Sarvas, H. O., Rautonen, N., Käyhty, H. M., KALLIO, M. J. T., & Mäkelä, O. (1990) · International Immunology · doi:10.1093/intimm/2.4.317 · Cited by 28
Watier, H. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.1.s29 · Cited by 26
Neurological symptoms suggestive of demyelination in Crohn??s disease after infliximab therapy
Dubcenco, E., Ottaway, C. A., Chen, D. L., & Baker, J. P. (2006) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200605000-00021 · Cited by 24
Cited by
Bruhns, P., Iannascoli, B., England, P., Mancardi, D. A., Fernandez, N., Jorieux, S., & Daëron, M. (2009) · Blood · doi:10.1182/blood-2008-09-179754 · Cited by 1,479
Therapeutic antibodies for autoimmunity and inflammation
Chan, A. C., & Carter, P. J. (2010) · Nature Reviews Immunology · doi:10.1038/nri2761 · Cited by 837
Glycosylation as a strategy to improve antibody-based therapeutics
Jefferis, R. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2804 · Cited by 829
Self-citationTerminal sugars of Fc glycans influence antibody effector functions of IgGs
Raju, T. S. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.06.007 · Cited by 521
Antibody–drug conjugates as novel anti-cancer chemotherapeutics
Peters, C., & Brown, S. (2015) · Bioscience Reports · doi:10.1042/bsr20150089 · Cited by 492
Metadata
- Authors
- Jefferis, R.
- Venue
- Expert Opinion on Biological Therapy
- Publisher
- Informa UK Limited
- Published
- 2007-08-29
- Volume
- 7
- Issue
- 9
- Pages
- 1401-1413
- ISSN
- 1471-2598 (ISSN-L)
- 1744-7682
- OpenAlex
- W2075219903
- Cited by
- 294
- References
- 89
- FWCI
- 14.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.